Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVenture Life Regulatory News (VLG)

Share Price Information for Venture Life (VLG)

Share Price is delayed by 15 minutes
Get Live Data
66.50    0.00 (0.00%)
Bid:
66.00
Ask:
67.00
Spread: 1.00 (1.515%)
Market Cap: £80.67m
VLG Live PriceLast checked at - London Stock Exchange

Intraday Venture Life Share Chart

30-year exclusive distribution deal signed

26 Jan 2015 07:00

RNS Number : 0861D
Venture Life Group PLC
26 January 2015
Β 

ο»Ώ

26 January 2015

Β 

Venture Life Group plc

Β 

("Venture Life" or "the Group")

Β 

30-year exclusive distribution deal with major skincare and cosmetics retailer in China

Β 

Venture Life Group plc (AIM: VLG), the international consumer products group addressing the self-care needs of the ageing population, announces that it has signed an exclusive 30-year distribution deal with one of the largest skincare and cosmetics retail chains in China.

Β 

The agreement is with REC Cosmetics (Shanghai) Limited ("REC"), a subsidiary of Gialen Group Co. Ltd ("Gialen"). Gialen is a privately owned business with 10,000 employees operating in over 1,000 of its own retail skincare and cosmetics stores across mainland China. Gialen is currently undertaking a rapid new store opening programme and over 300,000 customers currently visit their stores daily.

Β 

Under the terms of the distribution agreement, REC has the exclusive right to sell an initial range of 15 skincare products, including some products from Venture Life's anti-ageing range, ("the Initial Range") in China, Macau, Hong Kong and Taiwan. Venture Life will be the exclusive manufacturer and supplier to REC for all current and any future products under the agreement.

Β 

The Initial Range is expected to be launched in Gialen Group stores in China in the second half of 2015, subject to registration approval. For the Initial Range, contractual annual minimum purchase obligations ("MPO") have been agreed, the achievement of which maintains REC's rights to distribute the products. The MPO are worth approximately RMB 52.8m (Β£5.7m)* in sales for Venture Life over the first five years after product registration, including RMB 8.5m (Β£0.9m)* during the first year after registration. Over the full term of the agreement, the total MPO are worth approximately RMB 371m/Β£40m* in sales for Venture Life.

Β 

Jerry Randall, Chief Executive Officer of Venture Life, commented:

Β 

"We are delighted to have signed a very significant deal with such a progressive, fast-growing Chinese skincare and cosmetics business. We have worked through a very detailed process to arrive at this agreement with a partner who clearly shares our philosophy, ethos and ambition to grow in China.

Β 

"This agreement demonstrates there is a strong appetite for our products in China and the other territories, where the demand for high quality Western products, particularly in skincare, remains strong. Our Italian manufacturing capacity and capability has also been a major factor in securing this agreement, and further validates our strategic approach as an integrated product development, manufacturing and commercialisation company. We expect this deal to represent just the start of a very successful collaboration with Gialen in China."

Β 

* At current exchange rates as the Initial Range is priced in RMB.

- Ends -

Β 

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer

James Hunter, Chief Financial Officer +44 (0) 1344 742 870

Β 

Panmure Gordon (UK) Limited Freddy Crossley / Duncan Monteith +44 (0) 20 7886 2500Corporate Finance

Tom SalvesenCorporate Broking

Β 

Square1 Consulting

David Bick

Mark Longson +44 (0) 20 7929 5599

Β 

Notes to editors

Β 

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently include food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Β 

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical device and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

Β· food supplements to maintain brain function and memory;

Β· dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

Β· medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

Β 

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

Β 

About Gialen

Gialen was founded in 2005 and is headquartered in Guangzhou, China. Gialen is one of the largest cosmetics retail chains in China with over 1,000 stores and 300,000 customers daily.

Β 

Gialen sells an extensive range of products, listing some of the world's best known skincare, cosmetics and personal-care brands including L'Oreal, Shiseido, Olay and Nivea.

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
AGRBAMBTMBMTTAA
Date   Source Headline
1st Feb 20217:00 amRNSTrading Update & Notice of Results
14th Dec 20202:07 pmRNSIssue of Equity
11th Dec 20207:27 amRNSHolding(s) in Company
10th Dec 20204:45 pmRNSHolding(s) in Company
10th Dec 20204:41 pmRNSHolding(s) in Company
10th Dec 20202:42 pmRNSHolding(s) in Company
10th Dec 20201:45 pmRNSHolding(s) in Company
9th Dec 20202:28 pmRNSDirector/PDMR Shareholding
8th Dec 202012:00 pmRNSResult of General Meeting and Open Offer
24th Nov 20207:00 amRNSPDMR Dealings and Issue of Equity
23rd Nov 20208:52 amRNSHolding(s) in Company
20th Nov 20201:00 pmRNSPlacing, Open Offer and Notice of General Meeting
16th Nov 20209:05 amRNSSecond Price Monitoring Extn
16th Nov 20209:00 amRNSPrice Monitoring Extension
16th Nov 20207:00 amRNSResults of in-vitro clinical trial published
9th Nov 20204:40 pmRNSSecond Price Monitoring Extn
9th Nov 20204:36 pmRNSPrice Monitoring Extension
3rd Nov 20209:33 amRNS1000 Companies to Inspire Britain 2020 Report
19th Oct 202012:24 pmRNSHolding(s) in Company
15th Oct 20202:57 pmRNSExercise of Share Options & Voting Rights
9th Oct 20201:39 pmRNSHolding(s) in Company
5th Oct 20201:21 pmRNSHolding(s) in Company
24th Sep 20207:00 amRNSHalf-year Report
25th Aug 202011:59 amRNSHolding(s) in Company
24th Aug 20207:00 amRNSKey oral care brand - clinical trial on COVID-19
20th Jul 20209:05 amRNSSecond Price Monitoring Extn
20th Jul 20209:00 amRNSPrice Monitoring Extension
20th Jul 20207:00 amRNSHalf Year Trading Update
13th Jul 20207:00 amRNSAppointment of Joint Broker
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:36 pmRNSPrice Monitoring Extension
22nd Jun 202011:05 amRNSSecond Price Monitoring Extn
22nd Jun 202011:00 amRNSPrice Monitoring Extension
11th Jun 20207:00 amRNSHolding(s) in Company
9th Jun 20207:00 amRNSTrading update
3rd Jun 202010:52 amRNSResult of AGM
3rd Jun 20207:00 amRNSAGM Statement
29th May 20203:56 pmRNSHolding(s) in Company
20th May 20207:59 amRNSHolding(s) in Company
19th May 20203:26 pmRNSHolding(s) in Company
19th May 20203:25 pmRNSHolding(s) in Company
19th May 20201:29 pmRNSDirector/PDMR Shareholding
15th May 20207:00 amRNSComment on mouthwash & COVID-19 transmission
29th Apr 20204:15 pmRNSHolding(s) in Company
27th Apr 20209:06 amRNSSecond Price Monitoring Extn
27th Apr 20209:00 amRNSPrice Monitoring Extension
27th Apr 20207:00 amRNSExclusive Long Term Agreement Secured in China
16th Apr 20203:13 pmRNSHolding(s) in Company
9th Apr 20207:00 amRNSFinal Results
1st Apr 20203:10 pmRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.